BioLife Solutions has executed a new confidential agreement to supply its proprietary CryoStor cell freeze media to a T cell therapy customer. To date, BioLife has executed long-term supply agreements with Adaptimmune, Bellicum Pharmaceuticals, Celyad, Kite Pharma, TissueGene, TxCell and two unnamed customers.
"Execution of these supply agreements continues to demonstrate the critical role our proprietary biopreservation media products play in our customers' manufacturing, storage, and distribution processes,” Mike Rice, BioLife President & CEO, said. “CryoStor and HypoThermosol provide competitive cell manufacturing advantages that can reduce needle-to-needle time, extend shelf life, and improve the health and function of various types of T cells targeting blood cancers, solid tumors, and immune disorders."